- Home
- TBHC vs RLYB Comparison
TBHC vs RLYB Comparison
Compare TBHC & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBHC | RLYB |
|---|---|---|
| Founded | 1966 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 28.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TBHC | RLYB |
|---|---|---|
| Price | $1.00 | $10.66 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 90.1K | ★ 201.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $600,000.00 |
| Revenue This Year | N/A | $17.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.98 | $0.22 |
| 52 Week High | $2.40 | $11.20 |
Technical Indicators
Market Signals| Indicator | TBHC | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 92.99 |
| Support Level | $0.98 | $0.48 |
| Resistance Level | $1.29 | N/A |
| Average True Range (ATR) | 0.07 | 0.76 |
| MACD | 0.01 | 0.55 |
| Stochastic Oscillator | 8.04 | 89.39 |
Price Performance
Historical ComparisonAbout TBHC The Brand House Collective Inc.
The Brand House Collective Inc is a specialty retailer of home decor and gifts in the United States. The company stores provide various merchandise, including holiday decor, value pricing, and a stimulating in-store and online environment that provides customers with a brand experience. The company stores also offer an assortment of holiday merchandise in seasonal periods, as well as items that are suitable for gift-giving.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.